BofA analyst Tim Anderson reinstated coverage of Eli Lilly (LLY) with a Buy rating and $997 price target Eli Lilly is “likely to see bouts of volatility” on obesity-related news flow, but should be a core long-term holding due to its outsized, durable long-term growth and many “protective moats,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly to present Phase 3 results for Jaypirca at ASH meeting
- Eli Lilly announces $15B share repurchase program, 15% dividend increase
- M&A News: European Regulators Approve Novo Holdings’ Acquisition of Catalent (CTLT)
- Eli Lilly announces $3B expansion to Wisconsin manufacturing facility
- Dollar General reports mixed Q3, American Air raises Q4 outlook: Morning Buzz
Questions or Comments about the article? Write to editor@tipranks.com